Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Verastem (NASDAQ:VSTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)